Biocon Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021
October 21, 2021 at 01:48 pm EDT
Share
Biocon Limited reported earnings results for the second quarter and six months ended September 30, 2021. For the second quarter, the company reported sales was INR 18,404 million compared to INR 17,498 million a year ago. Revenue was INR 19,453 million compared to INR 17,653 million a year ago. Net income was INR 1,383 million compared to INR 1,693 million a year ago. Basic earnings per share from continuing operations was INR 1.16 compared to INR 1.43 a year ago. Diluted earnings per share from continuing operations was INR 1.16 compared to INR 1.41 a year ago.
For the six months, sales was INR 36,010 million compared to INR 34,436 million a year ago. Revenue was INR 37,531 million compared to INR 34,774 million a year ago. Net income was INR 2,227 million compared to INR 3,187 million a year ago. Basic earnings per share from continuing operations was INR 1.87 compared to INR 2.69 a year ago. Diluted earnings per share from continuing operations was INR 1.86 compared to INR 2.66 a year ago.
Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. It has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.
BIOCON LIMITED 
